Leerink Partnrs Issues Negative Estimate for CMPX Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Compass Therapeutics in a research note issued to investors on Tuesday, April 1st. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.17) per share for the quarter, down from their prior estimate of ($0.14). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. Leerink Partnrs also issued estimates for Compass Therapeutics' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.66) EPS and FY2026 earnings at ($0.76) EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01).

Several other research firms have also recently weighed in on CMPX. Guggenheim reissued a "buy" rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. Wedbush restated an "outperform" rating and issued a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday, April 1st. D. Boral Capital restated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 1st. HC Wainwright lifted their target price on Compass Therapeutics from $10.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Piper Sandler started coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target for the company. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Compass Therapeutics presently has an average rating of "Buy" and a consensus target price of $13.38.

Remove Ads

Compass Therapeutics Trading Up 0.3 %

CMPX traded up $0.01 during midday trading on Friday, reaching $1.58. The company's stock had a trading volume of 958,329 shares, compared to its average volume of 821,648. The company has a fifty day simple moving average of $2.73 and a 200 day simple moving average of $2.11. The stock has a market cap of $217.80 million, a P/E ratio of -4.26 and a beta of 1.40. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08.

Institutional Trading of Compass Therapeutics

Large investors have recently added to or reduced their stakes in the company. MPM Bioimpact LLC boosted its holdings in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. Enavate Sciences GP LLC bought a new position in Compass Therapeutics in the 4th quarter valued at $11,293,000. Tang Capital Management LLC boosted its stake in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. Rock Springs Capital Management LP grew its holdings in shares of Compass Therapeutics by 2.7% during the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock worth $8,380,000 after purchasing an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP increased its stake in shares of Compass Therapeutics by 2.6% in the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock valued at $4,284,000 after buying an additional 75,000 shares in the last quarter. 68.43% of the stock is owned by institutional investors.

Insider Transactions at Compass Therapeutics

In other news, insider Jonathan Anderman purchased 20,000 shares of the business's stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the acquisition, the insider now directly owns 21,000 shares of the company's stock, valued at approximately $32,340. This trade represents a 2,000.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 28.50% of the stock is currently owned by insiders.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.